Lexaria Bioscience Gestione

Gestione criteri di controllo 1/4

Lexaria Bioscience Il CEO è Rich Christopher, nominato in Aug2024, ha un mandato di meno di un anno. possiede direttamente 0.28% delle azioni della società, per un valore di $ 89.00K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.4 anni e 2.1 anni.

Informazioni chiave

Rich Christopher

Amministratore delegato

US$519.3k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.3%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Rich Christopher (54 yo)

less than a year

Mandato

US$519,317

Compensazione

Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024 and served as its Director since 2025. He served as Chief Financial Officer and T...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 89.0k
John Docherty	Chairman of the Scientific Advisory Board	9.8yrs	US$414.42k	0% $ 0
Michael Shankman	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Kristin Hamilton	Director of Operations	no data	Nessun dato	Nessun dato
Vanessa Carle	Head of Legal	no data	Nessun dato	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

0.4yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di LEXX non è considerato esperto (durata media 0.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 89.0k
John Docherty	Chairman of the Scientific Advisory Board	8.8yrs	US$414.42k	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Albert Reese	Independent Director	4.1yrs	US$74.83k	0.062% $ 19.4k
Christopher Bunka	Chairman of the Board	18.3yrs	US$884.84k	2.13% $ 664.9k
Nicholas Baxter	Independent Director	13.6yrs	US$74.83k	0.063% $ 19.6k
William McKechnie	Independent Director	9.4yrs	US$69.83k	0.075% $ 23.5k
Baljinder Bhullar	Director	less than a year	Nessun dato	0.074% $ 23.1k
Philip Ainslie	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Karen Aust	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

2.1yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LEXX non è considerato esperto (durata media del mandato 2.1 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/02/09 02:47
Prezzo dell'azione a fine giornata	2025/02/07 00:00
Guadagni	2024/11/30
Guadagni annuali	2024/08/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Lexaria Bioscience Corp. è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Ammar Shah	Eight Capital
Yi Chen	H.C. Wainwright & Co.
Michael Okunewitch	Maxim Group

Lexaria Bioscience Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Chief Executive Officer recently bought US$51k worth of stock

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Recent updates

Lexaria Bioscience Corp. Announces Dosing Has Begun in Its Fluorescently Tagged Dehydratech-Semaglutide Rodent Biodistribution Study

New major risk - Revenue and earnings growth

Less than half of directors are independent

Consensus revenue estimates fall by 12%

Lexaria Bioscience Corp. Announces Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings from Human Study GLP-1- H2 4-3

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide

Chief Executive Officer recently bought US$51k worth of stock

Consensus revenue estimates fall by 13%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products